AP-SA02
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bacteremia
Conditions
Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
Trial Timeline
Apr 26, 2022 → Jan 14, 2025
NCT ID
NCT05184764About AP-SA02
AP-SA02 is a phase 1/2 stage product being developed by Armata Pharmaceuticals for Bacteremia. The current trial status is completed. This product is registered under clinical trial identifier NCT05184764. Target conditions include Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05184764 | Phase 1/2 | Completed |
Competing Products
9 competing products in Bacteremia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Daptomycin + Comparator | Merck | Approved | 85 |
| Daptomycin for Injection | Merck | Phase 2 | 52 |
| Vancomycin + Daptomycin | Merck | Approved | 85 |
| Ceftolozane-Tazobactam + Meropenem | Merck | Phase 3 | 77 |
| Cefazolin IV + Linezolid IV + Vancomycin (IV) | Pfizer | Phase 3 | 76 |
| Aurexis® | Bristol Myers Squibb | Phase 2 | 51 |
| ceftobiprole medocaril | Basilea Pharmaceutica | Phase 2 | 47 |
| Ceftobiprole medocaril + Daptomycin | Basilea Pharmaceutica | Phase 3 | 72 |
| 514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II | XBiotech | Phase 1/2 | 33 |